Generate Biomedicines, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GENB | DNA | PBLS | PGEN | CADL | KARD | |
|---|---|---|---|---|---|---|
| Market cap | 1.78B | 793.94M | 3.58B | 2.74B | 748.35M | 1.34B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -6.1 | -4.1 | -13.2 | -34.8 | -15.6 | -4.9 |
| Price/book | 3.9 | 1.8 | 3.4 | 62.8 | 5.9 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +13.36% | −1.22% | −13.04% | +143.30% | +53.63% | −33.32% |
| Today | −3.49% | −9.31% | +5.35% | −1.92% | −1.61% | −2.18% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All GENB news ›Synthetic Biology in the Open
Researchers are sharing open source equipment designs, protocols, and code, but what is the synthetic biology community building with them? Synthetic biology is rooted in the idea that engineering principles of standardization, modularity,…
Generate Biomedicines doses first patient in AI-designed 'armored' CAR T trial for ovarian cancer
AllSci GB-5267 targets MUC16, also known as CA125, a transmembrane mucin overexpressed in more than 80% of ovarian tumors and implicated in tumor progression, metastasis, and immune evasion. The CAR T cells are armored to secrete IL-18…
Roswell Park, Generate Biomedicines Begin Trial of Armored CAR T
Roswell Park, Generate Biomedicines Launch Trial of AI-Engineered CAR T Therapy Genome Web Roswell Park, Generate Biomedicines Launch Trial of AI-Engineered CAR T Therapy
Head to Head Review: Generate Biomedicines (GENB) vs. Its Rivals
Posted by Michael Walen on Oct 4th, 2026 Generate Biomedicines (NASDAQ:GENB – Get Free Report) is one of 853 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Generate Biomedicines to…
Analyzing Generate Biomedicines (GENB) & Its Rivals
Posted by Tristan Rich on Oct 2nd, 2026 Generate Biomedicines (NASDAQ:GENB – Get Free Report) is one of 852 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Generate…
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ???Armored??? CAR T Therapy for Ovarian Cancer
Led by Principal Investigator Emese Zsiros, MD, PhD, FACOG, Chair of Gynecologic Oncology at Roswell Park, the phase 1 clinical trial (NCT07489287) will evaluate the safety and tolerability of GB-5267. Each patient’s T cells, immune cells…
ETFs Investing in Generate Biomedicines, Inc. Stocks — TradingView
ETFs Investing in Generate Biomedicines, Inc. Stocks TradingView Funds holding the stock
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
themarketsdaily.com2
-
tradingview.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.